A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with more than one million new diagnoses annually.

Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane ...

Oral and poster presentations of its DZD8586 study results in chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) are selected by ASCO Scientific Program Committee. In ...

Nuvalent, Inc. (NASDAQ:NUVL – Get Free Report) has been assigned an average rating of “Moderate Buy” from the eleven ratings ...